Dangers of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence
Krishna Sriram, Paul A. Insel
doi: https://doi.org/10.1101/2020.03.25.20043927
Krishna Sriram
*Departments of Pharmacology, University of California San Diego, La Jolla, California 92093, USA
Ph.D.Paul A. Insel
*Departments of Pharmacology, University of California San Diego, La Jolla, California 92093, USA
^Departments of Medicine, University of California San Diego, La Jolla, California 92093, USA
M.D.Article usage
Posted April 20, 2020.
Dangers of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence
Krishna Sriram, Paul A. Insel
medRxiv 2020.03.25.20043927; doi: https://doi.org/10.1101/2020.03.25.20043927
Subject Area
Subject Areas
- Addiction Medicine (405)
- Allergy and Immunology (714)
- Anesthesia (209)
- Cardiovascular Medicine (2986)
- Dermatology (254)
- Emergency Medicine (446)
- Epidemiology (12847)
- Forensic Medicine (12)
- Gastroenterology (839)
- Genetic and Genomic Medicine (4652)
- Geriatric Medicine (428)
- Health Economics (735)
- Health Informatics (2960)
- Health Policy (1076)
- Hematology (394)
- HIV/AIDS (938)
- Medical Education (430)
- Medical Ethics (116)
- Nephrology (478)
- Neurology (4441)
- Nursing (239)
- Nutrition (653)
- Oncology (2310)
- Ophthalmology (655)
- Orthopedics (260)
- Otolaryngology (328)
- Pain Medicine (285)
- Palliative Medicine (85)
- Pathology (504)
- Pediatrics (1205)
- Primary Care Research (506)
- Public and Global Health (7039)
- Radiology and Imaging (1557)
- Respiratory Medicine (927)
- Rheumatology (447)
- Sports Medicine (387)
- Surgery (494)
- Toxicology (60)
- Transplantation (213)
- Urology (186)